Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Charles Flexner

Charles Williams Flexner, MD

Director, AIDS Clinical Trials Unit; Deputy Director, Institute for Clinical and Translational Research
Professor of Medicine

See Research on Pubmed

Male
Appointment Phone

410-955-1725

Main Location

The Johns Hopkins Hospital

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Director, AIDS Clinical Trials Unit; Deputy Director, Institute for Clinical and Translational Research
  • Professor of Medicine

Centers & Institutes

  • Clinical and Translational Research, Institute for

Expertise

Infectious Diseases, Internal Medicine

Research Interests

Antiviral chemotherapy; Clinical Pharmacology; Basic and clinical pharmacology of antiretroviral drugs; HIV protease inhibitors and entry inhibitors

Biography

Charles W. Flexner, M.D., is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His scientific contributions include work on the important roles of pharmacokinetic enhancement, adherence, and dosing frequency in the long-term management of HIV/AIDS. He has published extensively on anti-infective drug transport and metabolism, and metabolic drug interactions. Dr. Flexner is currently the Deputy Director of the Institute for Clinical and Translational Research at Johns Hopkins, where he serves as Program Director for Clinical Research Units. He also serves as Associate Vice-Chair for Academic Fellowship Programs in the Department of Medicine, and Associate Director of the Graduate Training Programs in Clinical Investigation of the Johns Hopkins University School of Medicine and Bloomberg School of Public Health. Dr. Flexner is the Principal Investigator of the Johns Hopkins University AIDS Clinical Trials Unit (ACTU) supported by the NIH, and was Chair of the AIDS Clinical Trials Group (ACTG) Translational Research and Drug Development (TRADD) Committee from 2009-2011. Dr. Flexner served as President of the American Federation for Medical Research (AFMR) in 1999-2000, and was President of the AFMR Foundation from 2001-2002. He is a member of the editorial board of 10 scientific journals. He currently serves as a consultant to the Bill and Melinda Gates Foundation and the Clinton Health Access Initiative, and served as a consultant on FDA reform to the United States House of Representatives.

Languages

  • English
  • Italian

Memberships

American Society for Clinical Pharmacology and Therapeutics; member, 1992-2011. Board of Directors, 1995-98, 2000-2003; Long Range Planning Committee, 1995-2001; Membership Committee, 1994-97; Scientific Program Committee, 1995-96; Education Committee, 1997-2000; Government Affairs Committee, 1998-2001 and 2005-2009; Vice-President, 2001-2002.

International Society for Antiviral Research; member, 1993-2007. Local Organizing Committee, Annual Meeting 2000; Scientific Program Committee 1999-2001.

American Federation for Medical Research; member since 1995; Medical School Representative 1995-1998. President, Eastern Section, 1998-2000. National Council, 1998–2002. President-Elect, 1999-2000. President, 2000-2001.

American College of Physicians, Council of Medical Specialties; ASCPT Representative 1997-99.

International AIDS Society; member since 1997; International Scientific Review Committee 1999-present; Program Committee 2002-3.

American Federation for Medical Research Foundation. Secretary-Treasurer, 1999-2000; President, 2001-2002.

American Society for Microbiology; member, 1999-2005.

The Healthcare Consortium; Board of Directors, 1999-2000.

Association for Patient-Oriented Research; member, 2002-2012; Board of Directors, 2005-2008.

Association for Clinical Research Training; member since 2002; Advocacy/Public Policy Committee, 2005-present.

Association of Subspecialty Professors, Councilor At-Large, 2006-2009.

International Antiviral Society - USA. Hepatitis Program Advisory Board Member, 2010-present.

Association for Clinical and Translational Science; member since 2012; Patient-Oriented Research Standing Committee Core Member 2012-present; Education and Evaluation Committee Member 2012-present.

Clinical Trial Keywords

  • Phase 4
  • Phase 3
  • Phase 2
  • Phase 1
  • Pharmacokinetics
Additional Resources +
  • Education +

    Training

    • Johns Hopkins University School of Medicine (Baltimore MD) (1982)

    Certifications

    • American Board of Internal Medicine / Internal Medicine (1986)
  • Research & Publications +

    Research Summary

    Clinical research activities investigate the clinical pharmacology of new anti-HIV therapies and drug combinations. Specific drug classes studied include HIV reverse transcriptase inhibitors, protease inhibitors, entry inhibitors (selective CCR5 and CXCR4 antagonists), and integrase inhibitors. Scientific objectives of clinical studies include characterization of early drug activity, toxicity, and pharmacokinetics. Additional objectives are characterization of pathways of drug metabolism, and identification of clinically significant harmful and beneficial drug interactions mediated by hepatic and intestinal cytochrome P450 isoforms.

    Selected Publications View all on PubMed

    1. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latentinfection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 5:512-517.
    2. Hendrix CW, Flexner C, MacFarland RT, Fuchs EJ, Redpath E, Bridger G, Henson GW. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44: 1667-1673.
    3. Speck RS, Flexner C, Tian C-J, Yu X-F. 2000. Comparison of human immunodeficiency virus type 1 Pr55Gag and Pr160Gag-Pol processing intermediates that accumulate in primary and transformed cells treated with peptidic and non-peptidic protease inhibitors. Antimicrob Agents Chemother 44: 1397-1403.
    4. Speck RR, Yu X-F, Hildreth, JE, Flexner C. 2002. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive HIV infection. J Infect Dis 186: 332-340.
    5. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J, Gallant JE, , Carson K, Siliciano RF, Flexner C. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42: 1189-1196.
    6. Flexner C. HIV drug development: the next 25 years. (Invited review). Nature Reviews Drug Discovery 2007; 6: 959-966.
    7. Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C, for the ACTG A5211 Study Team. Pharmacokinetic/ pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist vicriviroc in treatment-experienced HIV-infected patients. J Acq Immunodef Syndr 2010; 53: 598–605.
    8. Crawford KW, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard R, Stoker V, Lederman M, Flexner C. Age-related changes in the plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26: 635-643.
    9. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D, AIDS Clinical Trials Group A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of AIDS Clinical Trials Group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041–1052. [PMCID #2833234]
    10. Chen J, Garner RC, Lee LS, Seymour M, Fuchs EJ, Hubbard W, Parsons T, Pakes GE, Fletcher CV, Flexner C. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther 2010; 88: 796-800.
    11. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations and obstacles to their development. J Infect Dis 2011; 204: 669-674.
    12. Wang L, Soon GH, Seng K-Y, Li J, Lee E, Yong E-L, Goh B-C, Flexner C, Lee L. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob Agents Chemother 2011; 55: 4090-4095.
    13. Crawford KW, Ripin DHB, Levin AD, Campbell JR, Flexner C. Optimizing the manufacturing, formulation, and dosage of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. Lancet Infect Dis 2012; 12: 550–60.
    14. Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint N, Tannenbaum SR, Hendrix CW, Fuchs EJ. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acq Immunodef Syndr 2012; 61: 593-599.
    15. Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, Flexner C, Swindells S. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013; 8: 1807-1813.

    Lab

    Laboratory activities include the use of accelerator mass spectrometry (AMS) techniques to measure intracellular drugs and drugs metabolites. AMS is a highly sensitive method for detecting tracer amounts of radio-labeled molecules in cells, tissues, and body fluids. We have been able to measure intracellular zidovudine triphosphate (the active anabolite of zidovudine) in peripheral blood mononuclear cells from healthy volunteers given small doses of 14C-zidovudine, and have directly compared the sensitivity of AMS to traditional LC/MS methods carried out in our laboratory.

    Clinical Trials

    Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, Aberg J, Sanne I, Parsons T, Kashuba A, Rosenkranz SL, Kmack A, Ferguson E, Dehlinger M, Mildvan D, AIDS Clinical Trials Group A5073 Study Team. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of AIDS Clinical Trials Group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50:1041–1052. [PMCID #2833234; NIHMS #168892]

    Wilkin TJ, Su Z, Krambrink A, Long J, Greaves WL, Gross R, Hughes MD, Flexner C, Skolnik PR, Coakley E, Godfrey C, Hirsch M, Kuritzkes DR, Gulick RM, AIDS Clinical Trials Group A5211 Study Team. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected, treatment-experienced patients. J Acq Immunodef Syndr 2010; 54:470–476.

    Crawford KW, Spritzler J, Kalayjian R, Parsons T, Landay A, Pollard R, Stoker V, Lederman M, Flexner C. Age-related changes in the plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26: 635-643.

    Soon GH, Shen P, Yong E-L, Flexner C, Pham P, Lee LS. Pharmacokinetics of darunavir 900 mg and ritonavir 100 mg once daily when co-administered with efavirenz 600 mg once daily in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 2775-2780.

    Chen J, Garner RC, Lee LS, Seymour M, Fuchs EJ, Hubbard W, Parsons T, Pakes GE, Fletcher CV, Flexner C. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther 2010; 88: 796-800; published online October 27, 2010, as http://www.nature.com/doifinder/10.1038/clpt.2010.188.

     Wang L-Z, Lee L, Thuya W-L, Soon GH, Kong L-R, Nye P-L, Jon-Deoon E-L, Flexner C, Goh B-C. Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometry. J Mass Spectrometry 2011; 46: 202-208.

    Wang L, Soon GH, Seng K-Y, Li J, Lee E, Yong E-L, Goh B-C, Flexner C, Lee L. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob Agents Chemother 2011; 55: 4090-4095.

    Dooley KE, Park J-G, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C, and the ACTG 5267 Study Team. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acq Immunodef Syndr 2012; 59:455-462.

    Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint N, Tannenbaum SR, Hendrix CW, Fuchs EJ. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study. J Acq Immunodef Syndr 2012; 61: 593-599.

    Lee LS, Pham P, Flexner C. Unexpected drug-drug interactions in HIV therapy: induction of UGT1A1 and bile efflux transporters by efavirenz. Annals Acad Med (Singapore) 2012; 41: 559-562.

    Dooley KE, Sayre P, Borland, J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acq Immune Defic Syndr 2013; 62: 21-27. [October 15, 2012 Epub ahead of print]

    Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, Flexner C, Swindells S. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). 2013; 8: 1807-1813. [April 23, 2013 Epub ahead of print]

    Andrade A, Rosenkranz SL, Cillo A, Lu D, Daar E, Jacobson JM, Lederman M, Acosta E, Read S, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR, AIDS Clinical Trials Group A5248 Team. Three distinct phases of HIV-1 RNA decay in treatment-naïve patients receiving raltegravir-based antiretroviral therapy: ACTG A5248 study. J Infect Dis 2013; 208:884-891.

  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    Student Research Award, 1976, American Federation for Clinical Research.

    Phi Beta Kappa, 1978, Stanford University.

    Graduation with Distinction and Departmental Honors, 1978, Stanford University.

    Denison Research Scholar, 1980-81, Johns Hopkins University.

    Warfield Longcope Prize for Outstanding Performance in Clinical Medicine, 1982, The Johns Hopkins University School of Medicine.

    Alpha Omega Alpha, 1982, The Johns Hopkins University School of Medicine.

    Faculty Career Development Award in Clinical Pharmacology, July 1, 1990 to June 30, 1994, Pharmaceutical Manufacturers Association Foundation.

    Clinical Investigator Award, July 1, 1990 to June 30, 1993, National Institute of Allergy and Infectious Diseases, NIH.

    Leon I. Goldberg Young Investigator Award, 1994, American Society for Clinical Pharmacology and Therapeutics.

    Pfizer Visiting Professor of Medicine and Clinical Pharmacology, 1995, Stanford University School of Medicine, Stanford, California.

    Samuel S. Riven Visiting Professor of Medicine, 1999, Vanderbilt University School of Medicine, Nashville, Tennessee.

    Kimsey Visiting Professor of Microbiology, 2000, University of Louisville College of Medicine, Louisville, Kentucky.

    Professor’s Award for Distinction in Teaching in the Pre-Clinical Divisions for 1999-2000, The Johns Hopkins University School of Medicine.

    Leadership Development Program, 2003-2004, Johns Hopkins Medicine.

    Joseph E. Murray Lecturer, American Association of Plastic Surgeons, 2006.

    Visiting Professor, Department of Infectious Diseases, Universita degli Studi, Turin, Italy, 2008-2013.

    Visiting Professor, Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia, 2012.

    Honorary Fellow Award, presented annually to a single individual in recognition of career achievement in the field of clinical pharmacology, American College of Clinical Pharmacology, San Diego, September, 2012.

    Professional Activities

    American Society for Clinical Pharmacology and Therapeutics; member, 1992-2011. Board of Directors, 1995-98, 2000-2003; Long Range Planning Committee, 1995-2001; Membership Committee, 1994-97; Scientific Program Committee, 1995-96; Education Committee, 1997-2000; Government Affairs Committee, 1998-2001 and 2005-2009; Vice-President, 2001-2002.

    International Society for Antiviral Research; member, 1993-2007. Local Organizing Committee, Annual Meeting 2000; Scientific Program Committee 1999-2001.

    American Federation for Medical Research; member since 1995; Medical School Representative 1995-1998. President, Eastern Section, 1998-2000. National Council, 1998–2002. President-Elect, 1999-2000. President, 2000-2001.

    American College of Physicians, Council of Medical Specialties; ASCPT Representative 1997-99.

    International AIDS Society; member since 1997; International Scientific Review Committee 1999-present; Program Committee 2002-3.

    American Federation for Medical Research Foundation. Secretary-Treasurer, 1999-2000; President, 2001-2002.

    American Society for Microbiology; member, 1999-2005.

    The Healthcare Consortium; Board of Directors, 1999-2000.

    Association for Patient-Oriented Research; member, 2002-2012; Board of Directors, 2005-2008.

    Association for Clinical Research Training; member since 2002; Advocacy/Public Policy Committee, 2005-present.

    Association of Subspecialty Professors, Councilor At-Large, 2006-2009.

    International Antiviral Society - USA. Hepatitis Program Advisory Board Member, 2010-present.

    Association for Clinical and Translational Science; member since 2012; Patient-Oriented Research Standing Committee Core Member 2012-present; Education and Evaluation Committee Member 2012-present.

  • Videos & Media +

    Lectures and Presentations

    American Society of Microbiology Special Lecture on Horizons in Biotechnology. Lecture entitled, "Potential Use of Recombinant Vaccinia Virus Vectors as Vaccines," October, 1986, Sacramento, California.

     

    Canadian Infectious Diseases Society Research Lecture. Lecture entitled, "Vaccinia Virus as a Vehicle in the Development of Multiple Vaccines." Canadian Society of Clinical Investigation / Royal College of Physicians and Surgeons Annual Meeting, September, 1987Winnipeg, Manitoba.

     

    American Society of Tropical Medicine and Hygiene Symposium on Vaccine Development. Lecture entitled, "Vaccinia Virus as a Carrier for Vaccine Antigens," October, 1990, New Orleans, Louisiana.

     

    Edna McConnell Clark Foundation Lecture. Lecture entitled, "Strategies for the Delivery of Cloned Vaccine Antigens," April, 1991, Woods Hole, Massachusetts.

     

    Associates of Clinical Pharmacology Symposium Address. Lecture entitled, "Frontiers in AIDS Drug Development," April, 1991, San Diego, California.

     

    33rd Interscience Conference on Antimicrobial Agents and Chemotherapy Symposium on the Pharmacology of Antiretroviral Chemotherapy. Lecture entitled, "Concentration-Controlled Trial Methodology in the Development of an Antiretroviral Nucleoside," October, 1993, New Orleans, Louisiana,.

     

    Leon I. Goldberg Young Investigator Award Lecture. Lecture entitled, "Role of Clinical Pharmacology in the Early Development of Antiretroviral Drugs." American Society for Clinical Pharmacology and Therapeutics Annual Meeting, March, 1994, New   Orleans, Louisiana.

     

    International Society for Antiviral Research Plenary Address. Lecture entitled, "Protein Binding: What Is the Clinical Relevance?" International Society for Antiviral Research Annual Meeting. May, 1996, Urabandai, Japan.

     

    Fourth Conference on Retroviruses and Opportunistic Infections, Symposium on Basic and Clinical Pharmacology of Protease Inhibitors (Symposium Chair). Lecture entitled “Plasma Protein Binding and Pharmacodynamics of Protease Inhibitors,” January, 1997, Washington, DC.

     

    American Society for Clinical Pharmacology and Therapeutics/American Society for Pharmacology and Experimental Therapeutics Joint Symposium on Molecular Therapeutics of HIV. Lecture entitled “Basic and Clinical Pharmacology of New Antiretroviral Drugs,” March, 1997, San Diego, CA,.

     

    American Federation for Medical Research, Biomedicine ’97 Symposium on Clinical Research. Lecture entitled “Training the Clinical Investigator,” April, 1997, Washington, DC.

     

    Infectious Diseases Society of America Annual Meeting Symposium. Lecture entitled “Antiretroviral Drug Interactions: The Tar Pit or the Tar Baby?” September, 1997, San Francisco, CA.

     

    Fifth Conference on Retroviruses and Opportunistic Infections. Plenary Session on Antiretroviral Therapy. Lecture entitled “Pharmacologic Causes of Treatment Failure,” February, 1998, Chicago, IL.

     

    38th Interscience Conference on Antimicrobial Agents and Chemotherapy Symposium on Managing the Toxicity of HIV Therapy. Lecture entitled, "Antiretroviral Drug Interactions," September, 1998, San Diego, CA.

     

    International Society for Quality of Life Research Annual Meeting. Plenary Panel Discussion entitled “Use of Quality-of-Life Data in the Drug Approval Process,” November, 1999, Baltimore, Maryland.

     

    National Institutes of Health Roundtable on HIV Therapeutics: Drug Delivery, Devices, and Formulations (Session Chair). Lecture entitled, "Novel Drug Delivery and HIV: Hope or Hype?” April, 1999, Gaithersburg, MD.

     

    Drug Information Association Symposium on Conflict of Interest. Address entitled, “FDA Financial Disclosure: A Medical Perspective,” June, 1999, Washington, DC.

     

    International AIDS Society State-of-the-Art Symposium. Address entitled, “Assessing Pharmacologic Risk and Benefit,” September, 1999, Rome, Italy.

     

    American College of Toxicology Annual Meeting. Lecture entitled, “Do Unsafe Drugs Enter and Remain in the Marketplace?” November, 1999, Washington, DC.

     

    National Institute on Alcohol Abuse and Alcoholism Symposium on Alcohol Use and HIV Pharmacotherapy. Lecture entitled “HAART Metabolism and Pharmacogenetics,” April, 2000, Bethesda, Maryland.

     

    40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Meet-the-Experts Lecture entitled, "Antimicrobial Drug Interactions," September, 2000, Toronto, Ontario.

     

    Kimsey Lectureship, University of Louisville College of Medicine. Lecture entitled, “Why HIV-Infected Patients Fail Therapy,” October, 2000, Louisville, KY.

     

    Eighth Conference on Retroviruses and Opportunistic Infections Symposium on Drug Transporters (Session Chair). Lecture entitled “Drug Transporters and HIV Pathogenesis,” February, 2001, Chicago, IL.

     

    Community Programs for Clinical Research on AIDS Annual Meeting. Plenary lecture entitled “Evidence-Based Pharmacology,” June, 2001, Washington, DC.

     

    International Congress of Therapeutic Drug Monitoring and Clinical Toxicology Symposium on Therapeutic Drug Monitoring for Antiretrovirals (Session Chair). Lecture entitled, “Integrating Adherence, Genotype, Phenotype, and TDM,” September, 2001, Washington, DC.

     

    FDA College Course on Pharmacogenetics: A Tool for Drug Development and Individualization of Disease Management. Lecture entitled “Genetic Causes, Genetic Solutions, and the Future of Pharmacology,” April, 2002, Rockville, MD.

     

    American Association for Clinical Chemistry Annual Meeting. Lecture entitled “Therapeutic Drug Monitoring, Pharmacogenomics, and Biomarkers for AIDS,” February, 2003, Baltimore, MD.

     

    American Society for Clinical Pharmacology and Therapeutics Annual Meeting. Meet the Professors Session entitled “Current Concepts in Developing Drugs for HIV and Other Viral Diseases,” April, 2003, Washington, DC.

     

    American Association for Clinical Chemistry Annual Meeting. Lecture entitled “Therapeutic Drug Monitoring, Pharmacogenomics, and Biomarkers for AIDS,” February, 2003, Baltimore, MD.

     

    Society of Toxicologic Pathology. Plenary lecture entitled “Genetic Causes, Genetic Solutions, and the Future of Pharmacotherapy,” June, 2003, Savannah, GA.

     

    International AIDS Society Conference on HIV Pathogenesis and Treatment. State-of-the Art talk entitled “The New Biology of Drug Transporters and Drug Metabolizing Enzymes: Implications for Clinical Practice,” July, 2003, Paris, France.

     

    11th Conference on Retroviruses and Opportunistic Infections. Workshop entitled “Pharmacologic Monitoring of Complex Patient Scenarios” (Session Chair and Panelist). February, 2004, San Francisco, CA.

     

    American Society for Clinical Pharmacology and Therapeutics Annual Meeting Symposium on Method Effectiveness versus Use Effectiveness. Lecture entitled “Causality, Inference, and Pharmacokinetics as a Biomarker,” March, 2004, Miami, FL.

     

    NIH, NIAID Office of Scientific Resource Development Course. Lecture entitled “Genes, the Environment, and Drugs: A Pharmacogenetics Primer,” April, 2005, Rockville, MD.

     

    First International Workshop on Clinical Pharmacology of Hepatitis Therapy. Plenary Talk entitled “Potential for Drug-Drug Interactions in the Treatment of Hepatitis B and C,” April, 2005, Quebec, Canada.

     

    Joseph E. Murray Lecturer, American Association of Plastic Surgeons. Lecture entitled “The Inviolable Social Contract: Education and the Academic Medical Center,” May, 2006, Hilton Head, SC.

     

    15th Conference on Retroviruses and Opportunistic Infections. Symposium address entitled “The Pharmacology of Aging: Implications for HIV Therapy.” February, 2008, Boston, MA.

     

    Drug Information Association Symposium on Improving Drug Development Using Patient Adherence Data in Clinical Trials. Keynote Speaker, address entitled, “Why Adherence Can Be a Matter of Life and Death: Adherence, Convenience, and Dosing Frequency as Determinants of Outcome in Antiretroviral Therapy.” May, 2008, Washington, DC.

     

    Sixth International Workshop on HIV and Hepatitis. Plenary Speaker, address entitled “Role of Drug Interactions in the Management of Hepatitis Infections,” May, 2010, Tel Aviv, Israel.

     

    Second Italian Conference on AIDS and Retroviruses. Plenary Speaker, address entitled, “Horizon Scanning: The Future of Antiretrovirals.” June, 2010, Brescia, Italy.

     

    American Society for Nanomedicine and Division of AIDS, NIAID, conference entitled Nano- and Emerging Technologies for HIV/AIDS. Plenary Speaker, address entitled “HIV Pharmacology and Product Development,” October, 2010, Potomac, MD.

     

    Twelfth International Workshop on the Clinical Pharmacology of HIV Therapy. Plenary Speaker, address entitled “A Tale of Two Viruses: Pharmacology’s Role in the Management of Hepatitis Virus Infections,” April, 2011, Miami, FL.

     

    14th International Workshop on the Clinical Pharmacology of HIV Therapy. Plenary Speaker, address entitled “The Role of Protein Binding and Stereochemistry in Drug-Drug Interactions,” April, 2013, Amsterdam, NL.

     

    ICAAC 2014. Convener for Workshop/Course entitled “Clinical Pharmacology Update on Antiretrovirals for HIV Treatment and Prevention,” and session speaker; lecture entitled “Coformulation, Compaction, and Simplification: How Much Difference Does It Really Make?” September, 2014, Washington, DC

  • Events +
  • Contact & Locations +

    Locations

    The Johns Hopkins Hospital
    600 N. Wolfe Street
    Osler
    503
    Baltimore, MD 21287
    Phone: 410-955-9712
    Appointment Phone: 410-955-1725
    Location Map

    Department/Division

    • Medicine

    For Research Inquiries Contact

    The Johns Hopkins Hospital
    Osler 575
    410-955-9712
    Fax Number: 410-955-9708
    E-mail address: flex@jhmi.edu

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer